Gus Alva, MD, DFAPA

Articles by Gus Alva, MD, DFAPA

Final Thoughts on Improving Access and Care

ByGus Alva, MD, DFAPA,Rishi Kakar, MD,Philip Harvey, MD,Gerald Maguire, MD

January 19th 2026

Panelists discuss how collaboration, innovation, and stigma reduction are key to transforming schizophrenia care.

Addressing Access Barriers and Formulary Restrictions

ByGus Alva, MD, DFAPA,Rishi Kakar, MD,Philip Harvey, MD,Gerald Maguire, MD

January 19th 2026

Panelists discuss how addressing payer restrictions and leveraging data-driven advocacy are essential for timely access to care.

Emerging Therapies in Schizophrenia

ByGus Alva, MD, DFAPA,Rishi Kakar, MD,Philip Harvey, MD,Gerald Maguire, MD

January 12th 2026

Panelists discuss how emerging therapies targeting new pathways may revolutionize schizophrenia management.

Comparing Safety Profiles and Health Care Costs

ByGus Alva, MD, DFAPA,Rishi Kakar, MD,Philip Harvey, MD,Gerald Maguire, MD

January 12th 2026

Panelists discuss how optimizing safety and cost-efficiency are central to improving adherence and overall health care value.

Use of Xanomeline/Trospium in Clinical Practice

ByGus Alva, MD, DFAPA,Rishi Kakar, MD,Philip Harvey, MD,Gerald Maguire, MD

January 5th 2026

Panelists discuss how integrating xanomeline/trospium into clinical practice may expand safe and effective treatment options.

Xanomeline/Trospium Mechanism of Action, Efficacy, and Safety

ByGus Alva, MD, DFAPA,Rishi Kakar, MD,Philip Harvey, MD,Gerald Maguire, MD

January 5th 2026

Panelists discuss how the muscarinic pathway of xanomeline/trospium offers a safer, nondopaminergic approach to schizophrenia care.

Switching Therapies, Managing Adverse Effects, and Adherence Challenges

ByGus Alva, MD, DFAPA,Rishi Kakar, MD,Philip Harvey, MD,Gerald Maguire, MD

December 29th 2025

Panelists discuss how balancing adverse-effect management with adherence optimization drives effective therapy transitions.

First- and Second-Generation Antipsychotic Therapies and Treatment Sequencing

ByGus Alva, MD, DFAPA,Rishi Kakar, MD,Philip Harvey, MD,Gerald Maguire, MD

December 29th 2025

Panelists discuss how thoughtful sequencing of antipsychotics enhances adherence, safety, and long-term efficacy.

Current Treatment Guidelines for Schizophrenia

ByGus Alva, MD, DFAPA,Rishi Kakar, MD,Philip Harvey, MD,Gerald Maguire, MD

December 22nd 2025

Panelists discuss how evidence-based, patient-tailored guideline adherence enhances long-term schizophrenia outcomes.

Addressing Social Determinants of Health and Unmet Needs in Schizophrenia

ByGus Alva, MD, DFAPA,Rishi Kakar, MD,Philip Harvey, MD,Gerald Maguire, MD

December 22nd 2025

Panelists discuss how addressing social and structural barriers is essential to achieving equitable outcomes in schizophrenia care.

Consequences of Relapse in Schizophrenia Care

ByGus Alva, MD, DFAPA,Rishi Kakar, MD,Philip Harvey, MD,Gerald Maguire, MD

December 15th 2025

Panelists discuss how relapse intensifies clinical and economic burdens, reinforcing the need for adherence and prevention-focused care.

Exploring Schizophrenia Progression and Its Impact on Quality of Life

ByGus Alva, MD, DFAPA,Rishi Kakar, MD,Philip Harvey, MD,Gerald Maguire, MD

December 15th 2025

Panelists discuss how early and sustained intervention can reshape schizophrenia’s chronic course and improve long-term quality of life.

Challenges of Early and Accurate Diagnosis in Schizophrenia

ByGus Alva, MD, DFAPA,Rishi Kakar, MD,Philip Harvey, MD,Gerald Maguire, MD

December 8th 2025

Panelists discuss how stigma and symptom overlap delay accurate schizophrenia diagnosis and how early intervention can transform outcomes.

Risk Factors for Schizophrenia

ByGus Alva, MD, DFAPA,Rishi Kakar, MD,Philip Harvey, MD,Gerald Maguire, MD

December 8th 2025

Panelists discuss how genetics, environment, and substance use interplay to shape schizophrenia risk and guide preventive care.

Symptoms Associated with Schizophrenia

ByGus Alva, MD, DFAPA,Rishi Kakar, MD,Philip Harvey, MD,Gerald Maguire, MD

October 31st 2025

Panelists discuss how understanding and managing the full range of schizophrenia symptoms is key to improving long-term patient outcomes.

Clinical and Economic Burden of Schizophrenia

ByGus Alva, MD, DFAPA,Rishi Kakar, MD,Philip Harvey, MD,Gerald Maguire, MD

October 31st 2025

Panelists discuss how schizophrenia’s immense personal and financial burden calls for early, integrated, and sustained care strategies.

Latest Updated Articles

Addressing Social Determinants of Health and Unmet Needs in Schizophrenia
Published: December 22nd 2025 | Updated:

Gus Alva, MD, DFAPA

Articles by Gus Alva, MD, DFAPA

Final Thoughts on Improving Access and Care

Addressing Access Barriers and Formulary Restrictions

Emerging Therapies in Schizophrenia

Comparing Safety Profiles and Health Care Costs

Use of Xanomeline/Trospium in Clinical Practice

Xanomeline/Trospium Mechanism of Action, Efficacy, and Safety

Switching Therapies, Managing Adverse Effects, and Adherence Challenges

First- and Second-Generation Antipsychotic Therapies and Treatment Sequencing

Current Treatment Guidelines for Schizophrenia

Addressing Social Determinants of Health and Unmet Needs in Schizophrenia

Consequences of Relapse in Schizophrenia Care

Exploring Schizophrenia Progression and Its Impact on Quality of Life

Challenges of Early and Accurate Diagnosis in Schizophrenia

Risk Factors for Schizophrenia

Symptoms Associated with Schizophrenia

Clinical and Economic Burden of Schizophrenia

Latest Updated Articles

Trending on AJMC

Congress Unveils Massive Funding Bill to Avert Shutdown

Gates Foundation, OpenAI Launch $50M AI Health Initiative in Africa

By Improving Sleep, TNX-102 SL Reduces Pain and Fatigue in Fibromyalgia

FDA Draft Guidance Proposes CR, MRD to Accelerate MM Drug Approval

SGLT2 Inhibitors Linked to Lower Risk of CKD, AKI Than GLP-1 RAs